Volume 111, Issue 1, Pages 30–31
Richard J. Paulson, M.D., M.S.
In July 2018 the U.S. Food and Drug Administration (FDA) approved, for the first time, an orally active gonadotropin-releasing hormone (GnRH) antagonist. My first thought was, I only wish that Gary Hodgen had lived long enough to see this day. I remember listening to his wonderfully prescient lectures on GnRH and its analogs in the early 1990s, dreaming of all that was going to be possible when the GnRH antagonists finally became a reality (1). Gary was a brilliant researcher and spent many years performing pioneering studies on prototypes of GnRH antagonists, which promised to transform reproductive medicine.